EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Agenus Chief Technology Officer Alex Duncan to Depart in January

Xconomy Boston — 

Alex Duncan, chief technology officer of Agenus (NASDAQ: AGEN) for nearly four years, is leaving on Jan. 2, the company disclosed in a securities filing Friday. No reason was given for Duncan’s departure. Lexington, MA-based Agenus develops cancer drugs. Last year, Agenus struck a $150 million deal with Gilead Sciences (NASDAQ: GILD), which acquired global rights to one Agenus drug candidate and options on two others.